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of Medicine, University of Oslo, Oslo, Norway; cDepartment of Community Medicine, Institute of Community Medicine, UiT the Arctic University of 
Norway, Tromsø, Norway
ABSTRACT
In Norway, the incidence of invasive meningococcal disease (IMD) is higher among 16–19-year-olds than 
in the general population. Most IMD cases among teenagers are caused by serogroup Y. Since 2011, one 
dose of meningococcal ACWY conjugate vaccine (MCV4) has been recommended for teenagers with out- 
of-pocket payment. The teenagers are usually vaccinated through the school health service at age 18. This 
study aimed to estimate costs and health gains of introducing MCV4 to Norwegian teenagers through the 
national immunization program (NIP). A Markov model was used to analyze the cost-effectiveness of 
universal MCV4 vaccination of either 15-year-olds or 18-years-olds. Occurrences of IMD were simulated 
from 15 until 23 years of age. Costs were estimated from a healthcare perspective. Sensitivity analyses 
evaluated the impact of vaccine price, vaccination uptake, IMD incidence and discount rate. Compared to 
today’s practice of vaccinating 18-year-olds with out-of-pocket payment, introducing MCV4 to 15-year- 
olds in a NIP-setting, with 90% vaccine uptake and 50% rebate on vaccine price, prevented 3.2 hospita-
lizations, 0.20 sequelae and 0.47 deaths among 15–23-year-olds, annually. Total costs were reduced by 
€30,000 and 9.7 quality-adjusted life-years (QALYs) were gained per birth cohort. The probability of cost- 
effectiveness was 99.0%, assuming a willingness-to-pay threshold of €86,000/QALY for severe diseases in 
Norway. Cost-effectiveness was highly dependent on vaccine price. Vaccination of 18-year-olds in a NIP- 
setting was also cost-effective, but less than NIP-vaccination of 15-year-olds. Introduction of MCV4 to the 
15-year-olds in the Norwegian NIP is likely to be cost-effective given a rebate on the vaccine price.
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Neisseria meningitidis, the meningococcus, is a common human 
commensal that in rare occasions cause invasive meningococcal 
disease (IMD). Despite antibiotic and supportive treatment, 
mortality from IMD remains high and many patients suffer 
sequelae influencing their quality of life (QoL).1,2 Serogroups 
A, B, C, W, X, and Y are the most common disease-causing 
variants.3 Incidence and serogroup distribution varies by region 
and age. IMD primarily affects infants, adolescents, and young 
adults.4 Serogroup B predominates in the general population in 
Europe.4,5
Rarity of the disease and unexpected affection of previously 
healthy individuals make the risk of IMD at an individual level 
unpredictable. Influence of long-term sequelae on the patient, as 
well as indirect effects on family members and society, are 
difficult to capture fully.6,7 In addition, the emergence of hyper-
virulent clones8,9 and unforeseen outbreaks with cases spread 
over time10,11 also predicts disease burden challenging at a public 
health level.
Both meningococcal ACWY conjugate vaccines (MCV4)12,13 
and meningococcal B protein vaccines (MenB)14,15 have been 
shown to induce protective immunity. Some European countries 
have a general recommendation for MCV4 vaccination of ado-
lescents, but adolescent MenB vaccination free of charge is 
currently not implemented in any national immunization 
program (NIP) in Europe.16 In Norway, meningococcal vaccines 
are not implemented in the NIP, and are currently only recom-
mended for various risk groups, including the 16–19-year-olds.
After a peak of 5.3 cases of IMD per 100,000 in 2010, the 
mean incidence in Norwegian 15–19-year-olds has decreased 
to 1.2 per 100,000 in 2017–2019.17 Between 2017 and 2019 the 
mean incidence was 0.8 per 100,000 in children <5 years, and 
0.3 per 100,000 in both the 5–14-year-olds and adults 
>19 years. Serogroup Y (75%) has predominated in the 15– 
19-year-olds, with no cases of serogroup B observed in this age 
group since 2014. In children <5 years, serogroup B (83%) has 
dominated, whereas serogroups W and Y are most prominent 
among the 5–14-year-olds (serogroups B 17%, C 17%, W 33%, 
Y 33%). Serogroups B, W, and Y were most common among 
adults >19 years (serogroups B 31%, C 4%, W 27%, Y 38%).
The majority of IMD cases in Norwegian teenagers has 
occurred among students taking part in the “russ” celebration, 
a tradition among upper secondary school graduates (mostly 
aged 18–19 years) including a month-long period of binge- 
drinking and partying with peers.18 Due to an observed 
increase in IMD among teenagers involved in the “russ” cele-
bration from 2009, a national recommendation for MCV4 
vaccination was initiated from 2011 for the 17–19-year-olds 
and expanded to the 16–19-year-olds in 2012. Vaccination is 
arranged through the school health service. Despite the 
CONTACT Sara Viksmoen Watle sara.watle@gmail.com Norwegian Institute of Public Health, P.O. Box 222 Skøyen, Oslo 0213, Norway.
HUMAN VACCINES & IMMUNOTHERAPEUTICS     
https://doi.org/10.1080/21645515.2021.1880209
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), 
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
national recommendation, MCV4 is not implemented for all 
teenagers in the national immunization program, and vaccine 
cost is financed with students paying out-of-pocket. Currently, 
several municipalities and counties are sponsoring MCV4 for 
one cohort (mostly 18–19-year-old graduates) in upper sec-
ondary school. In some areas, the vaccination uptake has 
increased from around 40% to 80% among graduates when 
vaccination is given free of charge and administered on school 
grounds,19 indicating that purchasing power and accessibility 
may influence MCV4 uptake among Norwegian teenagers. In 
2019, 48% of the 18–19-year-olds were vaccinated with MCV4 
nationally.19 This practice might have contributed to the 
observed recent decline in incidence of IMD in teenagers.17
Despite the currently low incidence of IMD, there is an 
ongoing debate in Norway whether MCV4 should be imple-
mented free of charge as part of the NIP for teenagers, to 
ensure equal access to vaccination and reduce inequality in 
health. This study aimed to perform an explorative evaluation 
of costs and health effects from a healthcare perspective to find 
out if introducing one dose of MCV4 to either 15-year-olds or 




Three different vaccination strategies were explored (Table 1): 1) 
vaccinating 18-year-olds as a risk group outside the NIP with 
out-of-pocket payment (Current practice); 2) vaccinating 15- 
year-olds free of charge as part of the NIP (Universal 15) or 3) 
vaccinating 18-year-olds free of charge as part of the NIP 
(Universal 18). Vaccination of 18-year-olds was chosen since 
this is when most Norwegian teenagers currently are vaccinated 
and engage in the “russ” celebration. Vaccination at 15 years of 
age was chosen as an alternative strategy, as most teenagers in 
Norway start upper secondary school at 15–16 years of age.
Model
We created a probabilistic Markov cohort model in R version 
3.6.2 simulating the impact of teenage MCV4 vaccination on 
survival, health-related QoL, and resource use from age 15 until 
105 years in yearly cycles for the three vaccination strategies. 
Occurrences of IMD were simulated for the period from 15 to 
23 years of age for all three strategies, according to vaccine 
effectiveness (VE) and vaccination uptake in each strategy 
(Figure 1). The age period 15–23 years of age was chosen to 
take into account the potential protection of the vaccine for all 5 
years after vaccination at either 15 or 18 years of age. Modeling 
was based partly on ideas and templates provided by the 
Decision Analysis in R for Technologies in Health group.20,21 
All individuals were assumed to be at risk of getting IMD, and all 
IMD cases were assumed admitted to hospital in the acute phase. 
Hospitalized patients would either recover, suffer permanent 
sequelae or die (Figure 2). Individuals started in the model in 
the health state susceptible and were at risk of the event IMD 
from either of the meningococcal strains A, C, W, or Y. 
Individuals who acquired IMD, and thus were hospitalized in 
the acute phase could from there move to the health state 
sequelae, or they could recover. All individuals were at risk of 
dying, although hospitalized patients or those with sequelae were 
at an increased risk of death.
Input parameters (Table 2) were based on sources from 
Norway where available, or from high-income countries with 
similar epidemiology or economy. Uncertain parameters in the 
model were incorporated as probability distributions and simu-
lated 1,000 times using Monte Carlo simulation. Probability 
distributions were created based on 95% confidence intervals 
(CI) or standard errors where available. For parameters where 
no information about the magnitude of the uncertainty was 
available in published sources, probability distributions were 
based on assumed uncertainty around the average of each para-
meter. One-way sensitivity analyses were based on average of 
runs of the probabilistic model for each extreme value.
Table 1. Overview of vaccination strategies used to model cost-effectiveness.
Strategy Age at vaccination (years) Vaccine uptake (%) Funding Vaccine rebate
Current practice 18 48 Out-of-pocket funding 0%
Universal 15 15 90 Free of charge in NIP 50%
Universal 18 18 90 Free of charge in NIP 50%




15 years 18 years 20 years 23 years





Figure 1. Illustration of time at risk of IMD, MCV4 vaccination uptake and duration of protection from MCV4 in all cohorts studied.  
IMD = Invasive meningococcal disease, MCV4 = meningococcal ACWY conjugate vaccine
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Health effects and costs were discounted according to 
Norwegian guidelines for single technology assessment (STA) 
of pharmaceuticals,23 hence 4% over the first 40 years, 3% from 
40 to 75 years and thereafter 2%. Due to the growing use of 
differential discounting of health and costs,6 we performed a 
separate analysis without discounting health effects, as sug-
gested in a Norwegian official report.24
Epidemiology
The average Norwegian cohort of 15-year-olds has been fairly 
consistent at around 65,000 individuals in the last years.25 The 
model only included IMD among age groups directly affected 
by the different vaccination strategies described above, and 
only included cases caused by MCV4-targeted serogroups. 
Data on IMD incidence were extracted from The Norwegian 
Surveillance System for Communicable Diseases (MSIS) 
between January 2008 and December 2017.17 Cases of IMD 
are mandatorily reported to MSIS and administration of vac-
cines to the Norwegian Immunisation Registry SYSVAK.19 The 
incidence of IMD in the study period might have been influ-
enced by the increase in MCV4 uptake from zero to nearly 50% 
in some age groups between 2008 and 2017. We wanted to 
compare the cost-effectiveness of the different vaccination 
strategies if each strategy had been implemented before the 
recommendation of MCV4 to 16–19-year-olds in 2011/2012 
induced a more widespread use of MCV4 among Norwegian 
teenagers. We therefore adjusted the observed cases of IMD 
registered in MSIS according to vaccination uptake in the 
cohorts registered in SYSVAK and the estimated vaccine effec-
tiveness, in order to calculate a “baseline” incidence of IMD if 
MCV4 had not been used among teenagers in 2008–2017. In 
this way, we were able to analyze differences in cost-effective-
ness between just a recommendation for the use of MCV4 
among selected 16–19-year-olds with out-of-pocket payment 
(Current practice) to that of implementing MCV4 in the 
national immunization program to a full cohort of teenagers 
with the vaccine fully financed by the government (Universal 
15 or Universal 18). With the adjusted incidences, we then 
calculated mean incidences for the full ten-year period (med-
ium incidence), the first five-year period (high incidence) and 
the last five-year period (low incidence) to incorporate the 
effect of incidence variations in the model. The number of 
IMD cases per birth cohort in each year was relatively low. 
The number of cases was therefore combined for the age 
groups 15–17, 18–19, and 20–23-year-olds, respectively, in 
order to even out random fluctuations in IMD (Table 2). 
Probabilities of sequelae (amputation, hearing loss, seizures, 
and skin scarring) were based on a review by Olbrich et al.2 The 
distributions of sequelae were based on medians, minimum 
and maximum values reported in the review.
Vaccine effectiveness and vaccination uptake
Assumed VE of MCV4 was extrapolated from a phase III 
immunogenicity study among 11–18-year-olds comparing two 
well-known types of MCV4.12 We pooled the percentage of 
seroconversion for different serogroups into one estimate 
based on a weighted average of effects for the diffe 
rent serogroups, giving a VE of 73% (95%CI 71–76%) (Table 2). 
Duration of protection was assumed to be 5 years.26,27 Possible 
waning of vaccine protection was not included in the model. 
Herd effect of MCV4 has only been shown in one study.28,29 
Since our study was explorative, we chose a static model not 
accounting for possible herd effect of MCV4.
The vaccine uptake in the universal strategies was assumed to 
be 90%, based on 88% uptake for the human papilloma virus 
vaccine and 93% for the diphtheria-tetanus-pertussis-polio 
booster among Norwegian 16-year-olds in 2018.30 In sensitivity 
analysis, the uptake in a NIP setting was varied between 80 and 
95%. With the current recommendation of out-of-pocket pay-
ment of MCV4 vaccination of 16–19-year-olds, vaccine uptake 
among 18–19-year-olds has gradually risen from 16% in 2012 to 
48% in 2018, adapted from ref. 19.19 Therefore, in the strategy, 
Current practice, the level of vaccine uptake was set to 48%.
Quality-adjusted life-year (QALY) weights
In order to comply with Norwegian guidelines for STA of 
pharmaceuticals,23 data on health-related QoL were based on 
the EQ-5D standardized generic instrument,31 and quality- 
adjusted life-year (QALY) weight among the healthy, general 
population was based on two Swedish studies32,33 (Table 2). 
QALY weights for hospital stay and for having sequelae were 
based on a previous economic evaluation.34 Patients with 
sequelae (amputation, skin scarring, hearing loss and seizures) 
were assumed to have sequelae for the rest of their lives. The 
event “hospital stay” was assumed to last for 10 days based on a 
publication by Stoof et al.35
Costs
Costs were calculated in European euro (€) with an exchange 







Figure 2. Markov model simulating the impact of vaccinating teenagers with MCV4.  
IMD = Invasive meningococcal disease, MCV4 = meningococcal ACWY conjugate vaccine






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4 S. V. WATLE ET AL.
average of exchange rates from 201836 (Table 2). In the strategy 
of Current practice, the price of MCV4 was based on the official 
retail price in Norway as given by the Norwegian Medicines 
Agency (NoMA).37 Vaccines included in the Norwegian NIP 
are procured through national tenders. In the two universal 
strategies, a 50% price rebate was assumed as a base case 
estimate. This rebate was extensively varied in a one-way 
sensitivity analysis from 25 to 75%, based on experience with 
tenders on long-term contracts for vaccines already implemen-
ted in the Norwegian NIP.
Costs of hospital stay were based on annually published 
official estimates for 2018 of average costs provided by the 
Norwegian Directorate of Health.38 These estimates are based 
on the diagnosis-related group (DRG) system, which has sepa-
rate groups for patients presenting with meningitis and septi-
cemia, the latter group divided into age groups above and 
below 18 years of age.
Time and resources used for school-based vaccination of 
adolescents were estimated using information provided by 
municipalities that are currently offering school-based menin-
gococcal vaccination. Probability distributions were assumed 
to vary between minimum and maximum of values provided 
by the different municipalities.
Norwegian guidelines for the management of IMD cases 
recommend prophylaxis with one dose of ciprofloxacin and 
one dose of MCV4 to close contacts of IMD cases. Costs and 
time spent on contact tracing and prophylactic treatment were 
based on information provided by municipal doctors and 
nurses. Estimates of number of hours spent on contact tracing 
was assumed as a lower and upper end of a confidence interval. 
Salaries for nurses and doctors were based on average hourly 
wages as reported by Statistics Norway.25 The estimate for the 
number of close contacts per IMD case was based on records 
from Norwegian IMD cases in the last decade. Estimates of 
lifetime costs for patients living with sequelae were based on a 
Canadian study from 2017.39 This study was chosen due to 
strong and rigorous reporting of all relevant costs related to 
sequelae. Canadian dollars were converted into NOK and 
adjusted based on consumer price index before being con-
verted into €.
According to Norwegian guidelines for STA of pharmaceut 
icals,23 costs were gathered based on an extended healthcare 
perspective, implying that factors as productivity loss arising 
from the inability to work were not included. The Norwegian 
guidelines explicitly state that health-related costs borne by 
patients and relatives should be included in the analyses. 
Thus, costs related to vaccines paid out-of-pocket by 48% of 
the graduating students in the scenario Current practice were 
included in the analysis, similar to costs related to a potential 
vaccination program free of charge to all teenagers. Costs of 
adverse events monitoring after MCV4 vaccination were not 
included in the model, because such events were assumed 
either minor and/or of short duration.40,41
When the ratio between incremental costs divided by incre-
mental effects (i.e., the incremental cost-effectiveness ratio 
(ICER)) is below a certain level (willingness-to-pay threshold), 
the intervention in question is regarded as cost-effective com-
pared to the comparator. We assumed a maximum willingness- 
to-pay threshold for cost-effectiveness of €86,000 
(NOK825,000) per QALY gained. The exact national threshold 
is uncertain, and our assumption was based on indications 
from two Norwegian official reports, proposing this maximum 
level for high priority diseases with high severity.24,42 There are 
yet no estimated threshold for Norway based on which health 
interventions are displaced when new health interventions are 
introduced. The best estimate so far is probably the estimate by 
Woods et al.,43 which translates to approximately €35,000 per 
QALY gained for 2018.
Results
Comparison of the strategies Current practice vs Universal 
15
Vaccinating a cohort of 15-year-olds with MCV4 as part of the 
Norwegian NIP with an estimated uptake of 90% (i.e., 
Universal 15) would result in 4.26 IMD-related hospitalizations 
during the 8-year-period from 15 to 23 years age, compared to 
7.41 hospitalizations if vaccinating 48% of 18-year-olds (i.e. 
Current practice) (Table 3). In the same period, a change 
from Current practice to Universal 15, would lead to a reduc-
tion of 0.47 deaths and 0.20 sequelae in each birth cohort. This 
means that about every 2 years we would avoid a death, and 
every 5 years a sequelae due to IMD caused by serogroups A, C, 
W, or Y if MCV4 was included in the NIP for 15-year-olds.
Expected discounted QALYs per individual would be 22.4 
with Current practice. Changing to the Universal 15 strategy 
would give a 0.00015 increase in expected QALYs per person, 
translating to 9.67 QALYs gained per birth cohort (Table 3). 
Total costs would decrease with €30,000, assuming 50% rebate 
on the vaccine price in the NIP-setting. This would give both a 
slight decrease in costs and an increase in effects, resulting in 
Universal 15 being what is referred to as a “dominant” strategy.
Our simulations indicated that there was a 100% chance of 
Universal 15 being more effective (i.e., giving more QALYs) 
than Current practice and a 54% chance of being less costly 
(Figure 3). Overall, there was a 99% chance of Universal 15 
being cost-effective compared to Current practice when assum-
ing a willingness-to-pay threshold of €86,000/QALY for severe 
diseases (Figure 4), although the uncertainty related to the 
input parameters indicates large variability around the esti-
mated cost-effectiveness ratio (Figure 3). Given the estimate 
of assumed displacement of other services, there was an 85% 
probability that introducing the MCV4 vaccine would give 
more health than the health displaced if the resources were 
taken from other health services (Figure 4).
Sensitivity and scenario analyses for the strategies 
Current practice vs Universal 15
Potential effects of variations in vaccine rebate, vaccination 
uptake, IMD incidence and discount rates on the ICER were 
explored comparing the Universal 15 strategy with Current 
practice in a tornado diagram (Figure 5).
Not surprisingly, a 75% rebate on the current MCV4 vac-
cine price in Norway was even more cost-effective than the 
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base case of 50% rebate. With only 25% rebate, the ICER would 
be €58,000 per QALY gained, which is still below the will-
ingness-to-pay threshold.
Changing vaccination uptake to 80% or 95% resulted in 
incremental increases in QALYs of 8.54 and 10.2, respectively, 
and differences in costs of -€186,000 and €49,000. Assuming a 
willingness-to-pay threshold of €86,000/QALY for severe dis-
eases, this resulted in both 80% and 95% uptake being cost- 
effective, and 80% uptake was also cost-saving.
Varying the IMD incidence from medium (i.e., the whole 
10-year period) in the base case to low (i.e., the last 5-year 
period) indicated a gain of 6.32 QALYs, while a change from 
medium to high incidence (i.e., the first 5-year period) gave a 
gain of 12.5 QALYs. Furthermore, a high incidence was cost- 
saving compared to the base case incidence, while the low 
incidence gave a small increase of €400 per cohort, giving an 
ICER of €63 per QALY gained.
When performing the analysis without discounting health 
effects, differences in QALYs increased to 26.6 per birth cohort 
when comparing Universal 15 to Current practice. Although 
incremental effect is considerably higher without discounting 
QALYs, the costs are the same, indicating that Universal 15 still 
produces more QALYs and reduces costs compared to Current 
practice.
We did also perform an analysis of the expected value of 
perfect information for all parameters (data not shown) based 
Table 3. Costs and health gains of vaccination with one dose of MCV4. Estimates are displayed per birth cohort. Current practice refers to today’s practice of vaccinating 
18-year-olds outside a NIP setting (48% uptake, retail vaccine price) and is therefore the base case strategy in the model. Universal 15 and Universal 18 refers to 
vaccination in a NIP setting (90% uptake, 50% rebate on vaccine price) of 15-year-olds and 18-year-olds, respectively. Estimates for the Universal 15 or Universal 18 











Costs and gains – Universal 15 vs Current 
practice




7.41 4.26 4.26 3.15 3.15
Sequelae (IMD-related*) 0.47 0.27 0.33 0.20 0.14
Deaths (any cause) 124.1 123.6 123.7 0.47 0.38
QALYs (discounted) 1,456,575 1,456,585 1,456,583 9.67 8.32
Costs** (€) (discounted) 1,600,000 1,570,000 1,580,000 − 30,000 − 20,000
NIP – national immunization program; IMD – invasive meningococcal disease; QALYs – quality-adjusted life-years; MCV4 – meningococcal ACWY conjugate vaccine 
* In the model, IMD-related deaths are added to deaths from other causes, while for hospitalizations we only count IMD-related. 
** Rounded to nearest 10,000
Figure 3. Scatterplot of simulations comparing the strategy Universal 15 with Current practice. Dotted red line represents the threshold for displaced health interventions 
of €35,000 per QALY and dashed blue line the willingness-to-pay threshold of €86,000 per QALY.  
QALYs = quality-adjusted life-years
Figure 4. Cost-effectiveness acceptability curve comparing the strategy Universal 15 (yellow line) with Current practice (green line). Dotted purple line represents 
threshold for displaced health interventions of €35,000 per QALY and dashed blue line the willingness-to-pay threshold of €86,000 per QALY.  
QALY = quality-adjusted life-year
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on methods developed by Strong and colleagues.44 Due to the 
high probability of cost-effectiveness and since only the vaccine 
rebate was informing this probability, the graph was not 
informative.
Comparison of the strategies Current practice vs Universal 
18
We also looked into potentially vaccinating the 18-year-olds 
instead of the 15-year-olds with MCV4 in a NIP-setting 
(Universal 18), with 90% uptake and 50% rebate on the vaccine 
price. Compared to Current practice, the Universal 18 strategy 
lead to an annual reduction of 3.2 hospitalizations, 0.14 seque-
lae, and 0.38 deaths per cohort. Lifetime QALYs gained was 
8.32 and costs were reduced by €20,000, giving an ICER below 
zero. The intervention had a 98% probability of being cost- 
effective compared to Current practice, when assuming a will-
ingness-to-pay threshold of €86,000/QALY for severe diseases 
(Figure 6).
The Universal 18 strategy averted fewer IMD cases and the 
probability of cost-effectiveness was lower compared to the 
Universal 15 strategy (Table 3). Since the Universal 18 strategy 
was both more costly and less effective, the Universal 18 strat-
egy was “dominated” by the Universal 15 strategy.
Discussion
Main findings
Vaccinating the 15-year-olds with one dose of MCV4 in a NIP- 
setting (Universal 15) is 99% likely to be cost-effective com-
pared to Current practice of vaccinating 18-year-olds with out- 
of-pocket payment, when assuming a willingness-to-pay 
threshold of €86,000/QALY for severe diseases in Norway. 
Changing from the strategy Current practice to Universal 15 
will prevent three hospitalizations annually, one sequelae every 
5 years and one death every 2 years among the 15–23-year- 
olds. In addition, the intervention will be cost-saving, with a 
reduction in incremental costs of €30,000. Vaccine price and 
incidence of IMD have the greatest impact on the probability of 
cost-effectiveness of implementing MCV4 for the 15-year-olds 
in the NIP.
Vaccination of the 18-year-olds as part of the NIP 
(Universal 18) was also found to be cost-effective compared 
to Current practice. However, as the incidence rate in 15–17- 
year-olds was more than double that of the 20–23-year-olds, 
the Universal 18 strategy was more costly and gave lower health 
gains than the Universal 15 strategy. We have previously shown 
that the meningococcal carriage rate in Norwegian teenagers 
was higher in upper secondary school students (15–19-year- 
olds) than in lower secondary school students (12–15-year- 
Figure 5. Tornado diagram of one-way sensitivity analysis on selected inputs with strategies Universal 15 compared to Current practice. Red indicates the lower 
boundaries and blue the upper boundaries for sensitivity analyses of input parameters in the model. Dotted line represents the threshold for displaced health 
interventions of €35,000 per QALY and dashed line the willingness-to-pay threshold of €86,000 per QALY. Black solid line represents input parameters used for base case 
cost-effectiveness calculations in the strategy Universal 15 (50% vaccine rebate, 90% vaccine uptake, medium IMD incidence and 2–4% discount rate). 
ICER = incremental cost-effectiveness ratio, QALY = quality-adjusted life-year, IMD = Invasive meningococcal disease
Figure 6. Scatterplot of simulations for comparing the strategies Universal 15 and Current practice (black dots) versus comparing Universal 18 and Current practice (gray dots). 
Dotted red line represents the threshold for displaced health interventions of €35,000 per QALY and dashed blue line the willingness-to-pay threshold of €86,000 per QALY. 
QALYs = quality-adjusted life-year
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olds).45 Since duration of protection from MCV4 is estimated 
to be at least 5 years,26,27 and since the incidence of IMD 
among the 15–17-year-olds is higher than among the 20–23- 
year-olds, it would be advantageous to vaccinate the 15-year- 
olds.
There is no official explicit threshold for cost-effectiveness 
in Norway. We have therefore compared our results in the 
likely lowest and highest thresholds that would be relevant 
for implementing a meningococcal vaccine in the Norwegian 
NIP. Assuming the levels of meningococcal disease observed 
during the past years, universal vaccination of the 15-year-olds 
would be cost-effective, regardless of whether the lowest or 
highest threshold for cost-effectiveness are used.
Comparison with other countries
Cost-effectiveness of MCV4 vaccination of adolescents in a NIP- 
setting has been evaluated in a few published studies.39,46–51 To 
our knowledge, our study is the first using a healthcare perspec-
tive and where the study population has not been primed with 
meningococcal vaccine in infancy. An Australian study using a 
healthcare perspective showed that introducing a booster dose of 
MCV4 to the 15–19-year-olds in addition to MCV4 at 12 months 
age would lead to an ICER above the current willingness-to-pay 
threshold and only a 35% probability of being cost-effective.47 In 
a US study, MCV4-vaccination of 11-year-olds without a catch- 
up would probably exceed the willingness-to-pay thresholds 
adapted for other vaccines implemented in the NIP.49 When 
assessing the same scenario, but with addition of a catch-up 
program, the intervention would be cost-effective from a societal 
perspective if accounting for herd immunity.48 Similarly, a 
Dutch study evaluating primary vaccination with MCV4 at 
14 months and a booster dose at 12 years of age showed cost- 
effectiveness when accounting for herd immunity.46 In Canada, 
where MCVC is provided at 12 months and MCVC or MCV4 in 
adolescence, switching from MCVC to MCV4 among the 12- 
year-olds would be cost-effective when assuming herd immunity 
and a high IMD incidence or declining vaccine prices.50
Some of the aforementioned studies were highly dependent 
on high IMD incidence and low vaccine price for a positive 
result, and the majority of the studies would not reach cost- 
effectiveness without accounting for herd effects.39,46–51 
Teenagers and young adults have higher rates of meningococ-
cal carriage and play an important role in transmission of the 
bacterium.52 Even though herd effects have been established 
for meningococcal conjugate vaccines against serogroup A 
(MCVA)53 and C (MCVC),54 there is only one study to our 
knowledge that has indicated possible herd effects for MCV4.28 
Adding herd effects would have made our results even more 
cost-effective, but without changing the conclusion. The will-
ingness-to-pay threshold for diseases with high severity such as 
IMD is much higher in Norway compared to many other 
European countries, as well as in Canada and 
Australia.39,46,47,50 In the UK for example, the threshold was 
for many years assumed to be between £20,000/QALY and 
£30,000/QALY, and later reduced to £12,936/QALY.55 In 
some cases with severe diseases, however, a threshold of 
£50,000 has been assumed. Similarly, the threshold in 
Norway has been estimated to about €35,000 per QALY,43 
although the government has decided to use thresholds in the 
range between €29,000/QALY and €86,000/QALY, depending 
on severity.24,42 Applying a lower threshold in our calculations 
would imply a lower probability of cost-effectiveness for 
MCV4 vaccination of Norwegian teenagers, but would not 
change the conclusion that the vaccination is both increasing 
health and reducing costs. As the epidemiology, vaccination 
programs, healthcare systems, insurance policies, and willing-
ness-to-pay thresholds are country-specific, comparison of 
cost-effectiveness of vaccine interventions between different 
countries are challenging.
Decisions regarding implementation of a meningococcal 
vaccine in the NIP
Cost-effectiveness analyses tend to disfavor interventions on 
rare and severe diseases such as IMD. Generating adequate 
data on the magnitude of long-term or late-onset sequelae 
and their impact on for example future productivity loss or 
the need for special education and social welfare, requires 
systematic and long-term follow-up of a significant number 
of patients.6 More subtle sequelae such as psychiatric, psycho-
social, or cognitive conditions may be difficult to capture fully 
and are probably underreported.56 Indirect effects on the QoL 
of relatives or caregivers of IMD patients can be significant,57 
but have not commonly been included in cost-effectiveness 
analyses.
With high developmental costs of new and technologi-
cally advanced vaccine platforms, some new vaccines have 
become expensive. If the decisions on whether to imple-
ment vaccines in a NIP were solely based on the interven-
tion being cost-effective, few of the more costly vaccines 
would have a chance of achieving cost-effectiveness, maybe 
affecting the incentive for further vaccine development 
against rare diseases like IMD. The challenge could partly 
be overcome by accepting higher willingness-to-pay thresh-
olds for more severe conditions such as recommended in 
Norwegian guidelines for STA of pharmaceuticals.23 
Another measure could be to adjust for the challenges of 
capturing the impact of long-term sequelae by adding a 
QALY adjustment factor, such as done by the Joint 
Committee on Vaccination and Immunisation in the UK.6 
Incorporating both a healthcare and a more broad societal 
perspective in the models might also contribute to a more 
balanced calculation.6
Fortunately, health technology assessments for publicly 
financed meningococcal vaccination lean on more than eco-
nomic evaluations. Other factors include societal preference 
and acceptability, equity in health6,7, and feasibility of the 
intervention. Unexpected affliction of previously young and 
healthy individuals induces anxiety in the population and 
high media uptake. Prevention of severe diseases and especially 
those affecting young people have a high priority both to the 
public and other stakeholders.7 Observations of a high vaccine 
uptake among the 18-year-olds with out-of-pocket payment in 
Norway19 indicate that the acceptability of MCV4 vaccination 
is high. Introducing MCV4 in the NIP would promote equity 
in access to health and probably increase the vaccine uptake 
among Norwegian teenagers, as already observed in regions 
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sponsoring MCV4. Including MCV4 in the NIP for the 15- 
year-olds would easily be feasible since the framework for 
vaccination is already established. From a political and public 
health perspective, a universal vaccination program against 
IMD might also mitigate the unforeseen costs related to out-
break responses10,11 and the need for rapid changes in immu-
nization practice.8,9
Strengths and limitations
Cost-effectiveness studies usually apply a societal perspective, 
sometimes combined with a health-care perspective. 
Experiences from some countries indicate that including a 
wide range of societal costs in the analysis may be pivotal for 
the outcome.6,7 By using a healthcare perspective, our model 
did not capture the costs and burdens of IMD fully, which 
might have underestimated the benefits of vaccination. 
However, adhering to the Norwegian government’s recom-
mendation of using a healthcare perspective makes our calcu-
lations more applicable for the Norwegian settings.
When exploring uncertainty of single parameters, the recom-
mended choice of modeling strategy is still to use a probabilistic 
model, as for instance pointed out by Claxton and colleagues.58 In 
essence, there are two ways to do this; the simple way shown in our 
tornado diagram (Figure 5) or an analysis of expected value of 
perfect information for parameters. We did also perform such an 
analysis based on methods developed by Strong and colleagues,44 
but due to high probability of the intervention being cost-effective 
(99%) and only one parameter informing this probability (the 
vaccine rebate), the graph was not informative. Instead, we 
included vaccine price, incidence of IMD and vaccination uptake 
in a tornado diagram as we believe these would be the most 
important parameters for Norwegian policy makers in the discus-
sion regarding implementation of MCV4 into the NIP for teen-
agers. In addition, a discount rate was included since there is an 
ongoing discussion in Norway whether to discount health 
effects.24
For all input data, we aimed at the best possible level of 
detail that would also be feasible in the model. In the case of 
sequelae after meningococcal disease, we found good sources 
for occurrence of different specific sequelae. For costs, how-
ever, our best available estimate was the estimate of lifetime 
loss due to different sequelae combined.39 Although these 
approaches to data for sequelae were clearly different, we con-
cluded that neither introducing more detail without data on 
one side nor reducing detail on the other side would make the 
model closer to a real life setting.
Country-specific data on mortality rate, frequency, quality- 
of-life impact and costs of acute and long-term sequelae from 
IMD were unfortunately not available from Norway. Using 
data from other countries with different epidemiology and 
healthcare systems might have over- or underestimated our 
results.
Vaccination uptake of MCV4 among Norwegian 18–19- 
year-olds is currently high (48%) and might have contributed 
to the observed drop in IMD incidence among Norwegian 
teenagers since 2010. We therefore attempted to wash out the 
effect of this MCV4 protection financed by out-of-pocket 
payments, to estimate a baseline incidence to assess a naïve 
population in all strategies. If the lower incidence of IMD was 
caused by natural fluctuation or other unknown factors instead 
of a vaccine effect, our incidence estimates might have been too 
high and might imply an overestimation of cost-effectiveness.
We did not account for waning of vaccine effectiveness 
during the eight-year study period, which might have over-
estimated vaccine protection. Cost-effectiveness studies from 
other countries evaluating implementation of adolescent 
MCV4 vaccination have assumed a VE similar to that for 
MCVC.39,46–51 The VE used in our model was based on 
assumed protection from serum bactericidal antibodies as a 
correlate of protection which, compared to other similar stu-
dies, might have underestimated the cost-effectiveness. 
However, more recent evaluations have indicated a lower VE 
for MCV459,60 compared to MCVC.
As mentioned, the present analysis was intended as an 
exploratory analysis to find out whether meningococcal vacci-
nation in Norway could be cost-effective. We therefore con-
structed a simpler Markov model instead of a more complex 
dynamic model. Since the intervention proved to be cost-effec-
tive in a Markov model, adding indirect effects would probably 
not change the conclusion of this study as such effects typically 
would avert even more IMD cases.
Conclusions
IMD is a rare, but highly severe disease striking young and pre-
viously healthy individuals unexpectedly. The benefits of menin-
gococcal vaccination are high and risks of adverse events low. In a 
NIP-setting in Norway, vaccinating the 15-year-olds with one dose 
of MCV4 would be more cost-effective than vaccinating the 18- 
year-olds, but vaccination at either age has a high probability of 
being cost-effective, assuming a high vaccination uptake and a 
rebate on the vaccine price in a national tender. Implementing 
MCV4 in the NIP free of charge would contribute to better equity 
in health and comply with both public and political desire. Future 
health economic evaluations should strive to obtain Norwegian 
data on the frequency, impact, and costs of short- and long-term 
sequelae in survivors of IMD. Furthermore, exploring the costs 
from a societal perspective and using a more complex and 
dynamic model to assess the impact of herd effects should be 
considered, especially if assessing cost-effectiveness of the more 
expensive meningococcal B vaccines.
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